Population characteristics at time of TNFi discontinuation (N=325)
| Age (years) | 52.6±13.1 |
| Female | 168 (51.9%) |
| BMI (kg/m2) | |
| Average | 30.1±6.5 |
| Normal | 61 (19.1%) |
| Overweight | 113 (34.8%) |
| Obese | 150 (46.1%) |
| Duration of PsA (years) | 9.8±8.1 |
| Duration of TNFi (years) | 1.5±1.6 |
| Tender joint count (mean±SD) | 0.66±1.13 |
| Swollen joint count (mean±SD) | 0.38±0.83 |
| Patient global assessment (mean±SD) | 20.2±19.0 |
| Physician global assessment (mean±SD) | 8.6±8.6 |
| CDAI (mean±SD) | 3.9±2.8 |
| mHAQ (mean±SD) | 0.20±0.32 |
| mDAS (mean±SD) | 2.4±0.6 |
| TNFi use | |
| 1st TNFi | 171 (52.6%) |
| 2nd TNFi | 101 (31.3%) |
| 3rd TNFi | 46 (14.2%) |
| 4th TNFi | 7 (2.1%) |
| TNFi monotherapy | 174 (53.5%) |
| TNFi+MTX | 137 (42.4%) |
| TNFi+prednisone | 24 (7.4%) |
BMI, body mass index; CDAI, clinical disease activity index; mDAS, modified disease activity score; mHAQ, modified health assessment questionnaire; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor.